We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session
Read MoreHide Full Article
Puma Biotechnology, Inc. (PBYI - Free Report) was a big mover last session, as its shares rose over 30% on the day. The move came after the Food and Drug Administration (FDA) advisory committee voted 12-4 recommending that Puma's breast-cancer drug neratinib be approved. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 95% in the past one-month time frame.
The company has seen two positive estimate revisions in the last 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Puma Biotechnology currently carriess a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Is PBYI going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session
Puma Biotechnology, Inc. (PBYI - Free Report) was a big mover last session, as its shares rose over 30% on the day. The move came after the Food and Drug Administration (FDA) advisory committee voted 12-4 recommending that Puma's breast-cancer drug neratinib be approved. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 95% in the past one-month time frame.
The company has seen two positive estimate revisions in the last 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Puma Biotechnology currently carriess a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Puma Biotechnology Inc Price
Puma Biotechnology Inc Price | Puma Biotechnology Inc Quote
Another top ranked stock from the Medical - Biomedical and Genetics space is VIVUS, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PBYI going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>